CX3CL1 and cardiovascular disorder: Genetic deletion of CX3CL1 or its cognate receptor dramatically reduces monocyte recruitment in the artery wall and the subsequent development of lesions in murine models of atherosclerosis, suggesting that the chemokine/receptor axis represents an attractive therapeutic target for clinical trials in cardiovascular disease [33].